Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Moxetumomab, an antibody targeting SIGLEC2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozoralizumab, an antibody targeting TNF × ALB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Idarucizumab, an antibody targeting Dabigatran.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enfortumab, an antibody targeting PVRL4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lanadelumab, an antibody targeting KLKB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gemtuzumab, an antibody targeting SIGLEC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Miromavimab, an antibody targeting Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-II.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Regdanvimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nepuvibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etesevimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ebronucimab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ormutivimab, an antibody targeting Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1.